NewAmsterdam Pharma reported its financial results for the first quarter ended March 31, 2025, with a robust $808.5 million in cash, cash equivalents, and marketable securities. This strong cash position provides a solid foundation for the company's ongoing clinical development and commercialization efforts.
The company's revenue for Q1 2025 was $2.98 million, marking a 113% increase from $1.4 million in the comparable period of 2024. The net loss for the quarter improved significantly to $39.53 million, compared to a net loss of $93.77 million in Q1 2024.
NewAmsterdam Pharma confirmed that its EMA submission, through its partner Menarini, remains on track for the second half of 2025. The company also highlighted recent data presentations at EAS and publications in The New England Journal of Medicine and The Lancet, reinforcing obicetrapib's differentiated product profile.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.